Comparison

Saikosaponin A European Partner

Item no. TMO-T2768-25mg
Manufacturer TargetMol
CASRN 20736-09-8
Amount 25 mg
Quantity options 100 mg 1 mL x 10 mM (in DMSO) 10 mg 1 mg 1 mL 20 mg 25 mg 50 mg 5 mg
Category
Type Molecules
Specific against other
Citations 1. Zhao H, et al. Exp Ther Med. 2015 Aug;10(2):823-827.
Smiles [H][C@@]12CC(C)(C)CC[C@@]11CO[C@@]22C=C[C@]3([H])[C@@]4(C)CC[C@H](O[C@]5([H])O[C@H](C)[C@H](O)[C@H](O[C@]6([H])O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)[C@H]5O)[C@@](C)(CO)[C@]4([H])CC[C@@]3(C)[C@]2(C)C[C@@H]1O
ECLASS 10.1 32169090
ECLASS 11.0 32169090
UNSPSC 12000000
Alias NF-kappaB inhibitor
Shipping Condition Cool pack
Available
Manufacturer - Targets
Liver X Receptor|||NF-κB|||Antibacterial
Shipping Temperature
Cool pack
Storage Conditions
-20
Molecular Weight
780.98
Description
Saikosaponin A has a variety of pharmacological benefits, including antiepileptic, anti-osteoporosis, antioxidant, anti-in ammatory, immunomodulatory, and anti-bacterial activities. It can effectively attenuate neuropathic pain in CCI rats by inhibiting the activation of p38 MAPK and NF-κB signaling pathways in spinal cord. It can inhibit NMDA receptor current and persistent sodium current, and inhibit the TNF-α level, the IL-1β production, and cysteine-aspartic acid protease (caspase)-1 activity.
Pathways
NF-κB|||Microbiology/Virology|||Metabolism

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 25 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close